Related references
Note: Only part of the references are listed.Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial
Evgeny Krupitsky et al.
LANCET HIV (2019)
Bayes factors for superiority, non-inferiority, and equivalence designs
Don van Ravenzwaaij et al.
BMC MEDICAL RESEARCH METHODOLOGY (2019)
Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial
Kristin Klemmetsby Solli et al.
EUROPEAN ADDICTION RESEARCH (2019)
Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial
Kim A. Hoffman et al.
BMC HEALTH SERVICES RESEARCH (2019)
A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment
Gregory Rudolf et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2018)
Extended-release injectable naltrexone for opioid use disorder: a systematic review
Brantley P. Jarvis et al.
ADDICTION (2018)
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial
Adam Bisaga et al.
DRUG AND ALCOHOL DEPENDENCE (2018)
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial
Sandra A. Springer et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2018)
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Joshua D. Lee et al.
LANCET (2018)
A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder
Milky Kohno et al.
DRUG AND ALCOHOL DEPENDENCE (2018)
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
Luis Sordo et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
Luis Sordo et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence A Randomized Clinical Noninferiority Trial
Lars Tanum et al.
JAMA PSYCHIATRY (2017)
Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial
Philip T. Korthuis et al.
ADDICTION (2017)
Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis
Andrea J. Low et al.
CLINICAL INFECTIOUS DISEASES (2016)
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders
Joshua D. Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A Comparison of Methods for Analyzing Viral Load Data in Studies of HIV Patients
Charles E. Rose et al.
PLOS ONE (2015)
The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients
E. Jennifer Edelman et al.
DRUG AND ALCOHOL DEPENDENCE (2014)
Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection: A North American Cross Cohort Analysis
Amy C. Justice et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Antiretroviral Treatment of Adult HIV Infection 2012 Recommendations of the International Antiviral Society-USA Panel
Melanie A. Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice
Stacey C. Sigmon et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2012)
Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months
Joshua D. Lee et al.
JOURNAL OF SUBSTANCE ABUSE TREATMENT (2012)
Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine
P. Todd Korthuis et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2011)
Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone
David A. Fiellin et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2011)
HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study
Frederick L. Altice et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2011)
Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program A Randomized Trial
Gregory M. Lucas et al.
ANNALS OF INTERNAL MEDICINE (2010)
The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study
Perrine Roux et al.
ADDICTION (2008)
Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence
David A. Fiellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
